公开(公告)号：EP1965827B1

公开(公告)日：2015-02-25

申请号：EP06838776.0

申请日：2006-12-01

申请人： Biogen Idec MA Inc.

发明人： MI, Sha ,  PEPINSKY, R., Blake ,  MCCOY, John

IPC分类号： A61K38/17 ,  A61K39/395 ,  C07H21/04

CPC分类号： C07K16/28 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0393 ,  A61K2039/505 ,  C07K14/4702 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C12N15/8509

摘要： The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. Additional methods include methods for inhibiting the binding of the Sp35 polypeptide with the ErbB2 polypeptide and a method for increasing ErbB2 phosphorylation by contacting oligodendrocytes with an effective amount of a composition comprising an Sp35 antagonist of the invention. Further embodiments of the invention include methods of inhibiting the binding of the Sp35 polypeptide with the ErbB2, increasing ErbB2 phosphorylation and promoting oligodendrocyte differentiation comprising contacting oligodendrocyte or oligodendrcoyte progenitor cells with an ErbB2 binding agent.

公开(公告)号：EP1789070A2

公开(公告)日：2007-05-30

申请号：EP05783641.3

申请日：2005-08-03

申请人： Biogen Idec MA, Inc.

发明人： MI, Sha ,  BROWNING, Jeffrey, L.

IPC分类号： A61K38/17

CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0356 ,  A61K38/191 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/70578 ,  C07K16/2878 ,  C07K2319/30 ,  C12N5/0619 ,  C12N15/8509 ,  C12N2501/25 ,  C12N2517/02 ,  G01N2333/70575

摘要： The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.

公开(公告)号：EP1776136B1

公开(公告)日：2012-10-03

申请号：EP05764255.5

申请日：2005-06-24

申请人： Biogen Idec MA Inc.

发明人： MI, Sha ,  PEPINSKY, R. Blake ,  MCCOY, John

IPC分类号： A61K38/17 ,  A61K39/00 ,  A61K31/7088

CPC分类号： G01N33/6893 ,  A61K38/17 ,  A61K38/1709 ,  C07K2319/30

公开(公告)号：EP2376120A2

公开(公告)日：2011-10-19

申请号：EP09829759.1

申请日：2009-11-24

申请人： Biogen Idec MA Inc.

发明人： MI, Sha ,  RHODES, Kenneth, J. ,  PEPINSKY, R., Blake

IPC分类号： A61K39/395

CPC分类号： C07K16/2878 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/00 ,  A61K38/177 ,  A61K39/39541 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/70578 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/14

摘要： The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.

摘要翻译： 本发明涉及到死亡受体6（DR6），其是肿瘤坏死因子（TNF）受体家族的成员，并且现在已经被证明是在神经系统中的细胞凋亡调控重要的蛋白质。此外，它具有 发现确实P75是DR6的配体。 其结果是，本发明涉及用于抑制DR6的相互作用和p75使用DR6和/或p75拮抗剂的方法。 此外，在所描述的方法包括用p75的拮抗剂使用DR6拮抗剂，任选地与p75拮抗剂组合的神经系统细胞的促销婷存活的方法，以及通过DR6拮抗剂的施用治疗神经变性病症的方法，任选地结合 ，

公开(公告)号：EP2217697A1

公开(公告)日：2010-08-18

申请号：EP08848257.5

申请日：2008-11-10

申请人： Biogen Idec MA Inc.

发明人： MI, Sha ,  PEPINSKY, R., Blake ,  MCCOY, John

IPC分类号： C12N5/00 ,  A01N37/18 ,  A61K31/70

CPC分类号： A61K38/1709 ,  A61K31/70 ,  A61K38/00 ,  A61K39/3955 ,  A61K48/00 ,  C07K14/47 ,  C07K14/70503 ,  C07K16/18 ,  C07K2317/76 ,  C07K2319/30 ,  C12N5/0622 ,  C12N2501/998 ,  C12N2502/08 ,  Y02A50/406

摘要： The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.

公开(公告)号：EP2068887A2

公开(公告)日：2009-06-17

申请号：EP08724452.1

申请日：2008-01-09

申请人： Biogen Idec MA Inc.

发明人： MI, Sha ,  PEPINSKY, R., Blake ,  SHAO, Zhaohui ,  GARBER, Ellen, A. ,  MIKLASZ, Steven, D.

IPC分类号： A61K31/70 ,  A61K39/395 ,  A61K38/16 ,  C07K14/00 ,  C07K16/00 ,  C07H21/00

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such as anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present disclosure provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The disclosure further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The disclosure further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

公开(公告)号：EP1965827A2

公开(公告)日：2008-09-10

申请号：EP06838776.0

申请日：2006-12-01

申请人： Biogen Idec MA Inc.

发明人： MI, Sha ,  PEPINSKY, R., Blake ,  MCCOY, John

IPC分类号： A61K38/17 ,  A61K39/395 ,  C07H21/04

CPC分类号： C07K16/28 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0393 ,  A61K2039/505 ,  C07K14/4702 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C12N15/8509

摘要： The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. Additional methods include methods for inhibiting the binding of the Sp35 polypeptide with the ErbB2 polypeptide and a method for increasing ErbB2 phosphorylation by contacting oligodendrocytes with an effective amount of a composition comprising an Sp35 antagonist of the invention. Further embodiments of the invention include methods of inhibiting the binding of the Sp35 polypeptide with the ErbB2, increasing ErbB2 phosphorylation and promoting oligodendrocyte differentiation comprising contacting oligodendrocyte or oligodendrcoyte progenitor cells with an ErbB2 binding agent.

公开(公告)号：EP2877166A1

公开(公告)日：2015-06-03

申请号：EP13822655.0

申请日：2013-07-26

申请人： Biogen Idec MA Inc.

发明人： GUCKIAN, Kevin ,  KUMARAVEL, Gnanasambandam ,  MA, Bin ,  MI, Sha ,  PENG, Hairuo ,  SHAO, Zhaohui ,  SUN, Lihong ,  TAVERAS, Arthur ,  WANG, Deping ,  XIN, Zhili ,  ZHANG, Lei

IPC分类号： A61K31/015 ,  A61K31/4375 ,  A61K31/44

CPC分类号： C07D451/02 ,  A61K31/136 ,  A61K31/196 ,  A61K31/439 ,  A61K31/445 ,  A61K31/46 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/5375 ,  A61K31/55 ,  A61K45/06 ,  C07B2200/07 ,  C07C217/22 ,  C07C229/46 ,  C07C229/48 ,  C07C255/59 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/42 ,  C07D209/52 ,  C07D211/34 ,  C07D211/62 ,  C07D217/22 ,  C07D221/22 ,  C07D223/06 ,  C07D295/096 ,  C07D401/06 ,  C07D471/08 ,  Y02A50/401

摘要： Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.

摘要翻译： 本发明公开了式（I）的双环芳基化合物确实可以调节汽车塔克（ATX）酶的活性。 本发明还涉及化合物确实是ATX抑制剂，以及制备和使用在脱髓鞘的治疗由于损伤或疾病搜索化合物，以及用于治疗增殖性疾病的方法：如癌症。

公开(公告)号：EP2068866A2

公开(公告)日：2009-06-17

申请号：EP07810708.3

申请日：2007-07-24

申请人： Biogen Idec MA Inc.

发明人： MI, Sha ,  JUNG, Vincent

IPC分类号： A61K31/365

CPC分类号： C07K14/71 ,  C07K14/705 ,  C07K2319/30

摘要： This invention relates to methods for promoting myelination, neuronal survival, and oligodendrocyte differentiation and treating demyelination and dysmyelination disease by the administration of a TrkA antagonist. The invention also relates to methods of inhibiting or decreasing Sp35 expression by the use of a TrkA antagonist. Additionally, the invention relates generally to methods for blocking Sp35 and TrkA interaction and inhibiting or decreasing TrkA phosphorylation by the administration of a Sp35 antagonist.

公开(公告)号：EP1776136A2

公开(公告)日：2007-04-25

申请号：EP05764255.5

申请日：2005-06-24

申请人： Biogen Idec MA Inc.

发明人： MI, Sha ,  PEPINSKY, R. Blake ,  MCCOY, John

IPC分类号： A61K38/17 ,  A61K39/00 ,  A61K31/7088

CPC分类号： G01N33/6893 ,  A61K38/17 ,  A61K38/1709 ,  C07K2319/30

摘要： The invention provides methods of treating diseases, disorsers or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist.